Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PROAIR DIGIHALER vs VOSOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (c AMP) in bronchial smooth muscle, resulting in bronchodilation.
Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.
FDA: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma),FDA: Prevention of exercise-induced bronchospasm
Treatment of superficial bacterial infections of the external auditory canal,Treatment of seborrheic dermatitis of the ear
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.
Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation
Terminal elimination half-life: 2–4 hours. Clinical context: Short half-life necessitates frequent dosing for sustained effect; prolonged in renal impairment.
Primarily metabolized by conjugation (sulfation) in the gastrointestinal tract and liver; minor CYP450 metabolism.
Acetic acid is metabolized via the Krebs cycle; hydrocortisone is hepatically metabolized primarily by CYP3A4.
Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2%
Renal: 95% as unchanged drug and metabolites; biliary/fecal: <5%.
Approximately 10% bound to plasma proteins (primarily albumin)
90–95%, primarily to albumin.
Vd of albuterol is approximately 1.0-4.0 L/kg (mean 2.5 L/kg), indicating extensive distribution into tissues
Vd: 0.3–0.5 L/kg; clinical meaning: moderate distribution into total body water, limited tissue penetration.
Inhalation: mean absolute bioavailability from a metered-dose inhaler is approximately 7% of the administered dose, though systemic exposure varies with inhaler technique
Otic: 80–90% (local absorption with minimal systemic).
No dose adjustment required for renal impairment. Albuterol is primarily hepatically metabolized and renally excreted as metabolites; however, no specific GFR-based guidelines exist.
No dosage adjustment required for renal impairment.
No specific dose adjustment recommended for hepatic impairment. Use with caution in severe hepatic impairment due to potential accumulation; monitor for adverse effects.
No dosage adjustment required for hepatic impairment.
Children 4-11 years: 90-180 mcg (1-2 inhalations) every 4-6 hours as needed. For exercise-induced bronchospasm: 90-180 mcg 15 minutes before exercise. Weight-based dosing not typically used; follow age-based guidelines.
Children: Instill 3 drops into the affected ear(s) 3-4 times daily; use as directed by physician.
No specific dose adjustment required. Use lowest effective dose due to potential increased sensitivity and comorbidities. Monitor for tachycardia, tremor, and hypertension.
No specific geriatric dosage adjustment; use same as adult dosing with caution for increased sensitivity.
No FDA black box warning.
None
Paradoxical bronchospasm with fatal outcomes; discontinue immediately if occurs,Life-threatening asthma exacerbations; need for increased use may indicate worsening asthma,Cardiovascular effects: increased heart rate, hypertension, arrhythmias; use with caution in patients with cardiovascular disorders,Hypokalemia and hyperglycemia; monitor serum potassium and glucose in susceptible patients,Rare anaphylactic reactions,Do not exceed recommended dose; excessive use may lead to death
For external use only,Not for use in eyes,Discontinue if irritation or sensitization occurs,Prolonged use may result in overgrowth of non-susceptible organisms,Use caution in perforated tympanic membrane
Hypersensitivity to albuterol or any component of the product
Hypersensitivity to any component,Viral infections of the ear (e.g., herpes simplex, varicella),Fungal infections unless treated with concomitant antifungal therapy
No specific food-drug interactions are known for albuterol. However, caffeine-containing foods and beverages (coffee, tea, cola, energy drinks) may potentiate the stimulant effects (e.g., tachycardia, tremor). Hypokalemia may be potentiated by concurrent use of potassium-depleting diuretics or prolonged use. Avoid high-sulfite foods if a sulfite sensitivity is present, as these may trigger bronchospasm in some asthmatics.
No known food interactions. Alcohol consumption is not restricted.
Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. In humans, inhaled beta-agonists are not associated with an increased risk of major congenital malformations. However, maternal asthma exacerbations pose significant risks to the fetus, including preterm birth and low birth weight. Therefore, the benefit of controlled asthma outweighs the theoretical risks. First trimester exposure is not linked to increased malformation rates. Second and third trimester use is considered safe, with no known fetal toxicity at standard doses. No specific teratogenic risk profile by trimester is established.
VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged systemic use may increase risk of orofacial clefts (first trimester) and fetal adrenal suppression. Acetic acid is considered low risk. Second/third trimester: minimal systemic absorption from otic use, but theoretical risk of adrenal suppression with high doses.
Albuterol is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 2.5, but the infant dose is estimated to be less than 1% of the maternal dose. Due to low oral bioavailability, significant infant exposure is unlikely. However, observe the infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability). The benefit of maternal asthma control generally outweighs the minimal risk to the breastfed infant.
No data on excretion in human milk; topical otic use likely results in negligible systemic absorption. Use caution. M/P ratio unknown.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may lead to lower serum concentrations of albuterol. However, clinical effectiveness typically remains sufficient. No routine dose adjustments are recommended; dosing should be guided by symptom control. In severe asthma exacerbations during pregnancy, higher doses or more frequent administration may be required. Monitor for maternal tachycardia and hypokalemia.
No dosing adjustments required for topical otic use due to minimal systemic absorption; use standard dose (5 drops in affected ear(s) 3-4 times daily). Avoid prolonged use (>10 days) to minimize potential systemic effects.
PROAIR DIGIHALER contains albuterol sulfate, a short-acting beta-2 agonist (SABA). It is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB). The device is breath-activated, requiring a low inspiratory flow rate (approx. 20 L/min) for optimal dose delivery. Shake well before each use. Priming is not needed for new inhalers if used within 2 weeks; if not used for more than 2 weeks, prime by releasing 1 test spray into the air. Rinse mouth with water after each use to reduce risk of oropharyngeal candidiasis. Avoid concomitant use of non-selective beta-blockers (e.g., propranolol) as they may antagonize bronchodilatory effects. Monitor for paradoxical bronchospasm, tachycardia, and hypokalemia. Not for acute severe asthma exacerbation requiring intensive care; use a nebulized SABA or IV bronchodilator instead.
VOSOL HC contains acetic acid (2%) and hydrocortisone (1%) in a propylene glycol vehicle. It is indicated for the treatment of otitis externa (swimmer's ear), particularly when inflammation is present. The acetic acid lowers the p H to ~3-4, creating an unfavorable environment for bacteria and fungi. Hydrocortisone reduces inflammation and pruritus. Do not use in patients with a perforated tympanic membrane (risk of ototoxicity). The solution should be instilled with the patient's head tilted to the side, and the tragus massaged to facilitate penetration. Use the dropper provided; do not allow the dropper tip to contact the ear canal to avoid contamination. Duration of therapy typically 7-10 days.
Use exactly as prescribed; do not exceed recommended doses.,Shake the inhaler well before each use.,Exhale fully, place mouthpiece between lips, inhale deeply and forcefully to activate the dose; hold breath for 10 seconds, then exhale slowly.,Rinse mouth with water after each use to prevent mouth and throat irritation.,Do not use if the inhaler has been dropped or damaged; check dose counter regularly.,Seek emergency medical attention if breathing problems worsen despite using this medication.,Avoid foods or beverages that may trigger asthma symptoms, such as sulfites (e.g., dried fruits, wine).,Avoid caffeine (coffee, tea, soda) as it may increase side effects like nervousness and rapid heartbeat.,Stay hydrated but avoid large amounts of cold water immediately before or after use.
Instill 5 drops into the affected ear(s) 3-4 times daily for 7-10 days.,Keep the dropper tip clean; do not touch the tip to any surface, including the ear.,Tilt head sideways and stay in that position for 5 minutes after instilling drops.,Do not use if you have a punctured eardrum or ear tubes.,Notify your doctor if symptoms persist after 7 days or worsen.,This medication contains benzalkonium chloride (preservative) and propylene glycol; may cause contact dermatitis in sensitive individuals.,Avoid swimming or getting water in the ear during treatment.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PROAIR DIGIHALER vs VOSOL HC, answered by our medical review team.
PROAIR DIGIHALER is a Beta-2 Agonist Bronchodilator that works by Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (c AMP) in bronchial smooth muscle, resulting in bronchodilation.. VOSOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid provides antibacterial and antifungal activity by acidifying the ear canal and disrupting microbial cell membranes. Hydrocortisone suppresses inflammatory mediators.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PROAIR DIGIHALER and VOSOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PROAIR DIGIHALER is: 90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.. The standard adult dose of VOSOL HC is: Instill 5 drops into the affected ear(s) 3-4 times daily, or as directed by physician.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PROAIR DIGIHALER and VOSOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PROAIR DIGIHALER is classified as Category C. Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinical. VOSOL HC is classified as Category C. VOSOL HC (acetic acid, hydrocortisone) otic solution: Pregnancy Category C. No adequate human studies; avoid use unless clearly needed. Hydrocortisone crosses placenta; prolonged s. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.